Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states

Regulatory Peptides

Volumn 159, Issue 1-3, 2010, Pages 61-66

  Nuche Berenguer, Bernardo ^a   Moreno, Paola ^a   Portal Nuñez, Sergio ^a   Dapía, Sonia ^b   Esbrit, Pedro ^a   Villanueva Peñacarrillo, María L ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Empresa de Base Tecnológica S L   (Spain)

Author keywords

Bone remodeling; Exendin 4; Insulin resistance; Type 2 diabetes; Wnt pathway

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DICKKOPF 1 PROTEIN; EXENDIN 4; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SCLEROSTIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; INSULIN RESISTANCE; MALE; MICRO-COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; BONE MORPHOGENETIC PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FRUCTOSE; GASTRIC INHIBITORY POLYPEPTIDE; GENETIC MARKERS; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LDL-RECEPTOR RELATED PROTEINS; MALE; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROSIS; PEPTIDES; RATS; RATS, WISTAR; SWEETENING AGENTS; VENOMS; WNT PROTEINS;

MAMMALIA; RATTUS;

EID: 71449084965     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.06.010     Document Type: Article

References (50)

1. Inzerillo A., and Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Dis 5 (2004) 261-268
2. Clowes J.A., Khosla S., and Eastell R. Perspective potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 9 (2005) 1497-1506
3. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., Byrjalsen I., Krarup T., Holst J.J., and Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18 (2003) 2180-2189
4. Bollag R.J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., Mulloy A.L., Rasmussen H., Qin F., Ding K.H., and Isales C.M. Osteoblasts-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141 (2000) 1228-1235
5. Xie D., Zhong Q., Ding K.H., Cheng H., Williams S., Correa D., Bollag W.B., Bollag R.J., Insogna K., Troiano N., Coady C., Hamrick M., and Isales C.M. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 40 (2007) 1352-1360
6. Creutzfeldt W. The entero-insular axis in type 2 diabetes. Incretins as therapeutic agents. Exp Clin Endocrinol Diab 109 (2001) S288-S303
7. Yamada C., Yamada Y., Tsukiyama K., Yamada K., Udagawa N., Takahashi N., Tanaka K., Drucker D.J., Seino Y., and Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149 (2008) 574-579
8. Nuche-Berenguer B., Moreno P., Esbrit P., Dapía S., Caeiro J.R., Cancelas J., Haro-Mora J.J., and Villanueva-Peñacarrillo M.L. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic and insulin-resistant states. Calcif Tissue Int 84 6 (2009) 453-461
9. Larsen P.J., and Holst J.J. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 15 (2005) 97-107
10. Nikolaidis J.A., Sokos M.a.n.k.a.s.S., GG M.I.s.k.a.G., Shah A., Elahi D., and Shannon R.P. Effects of glucagon-like peptide in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
11. Chen Y.E., and Drucker D.J. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272 (1997) 4108-4115
12. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 15 (1992) 7402-7405
13. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exedin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88
14. Fineman M.S., Bicsak T.A., Shen L.Z., Taylor K., Gaines E., Varns A., Kim D., and Baron A.D. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26 (2003) 2370-2377
15. Alcántara A.I., Morales M., Delgado E., López-Delgado M.I., Clemente F., Luque M.A., Malaisse W.J., Valverde I., and Villanueva-Peñacarrillo M.L. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 341 (1997) 1-7
16. Sancho V., Trigo M.V., González N., Valverde I., Malaisse W.J., and Villanueva-Peñacarrillo M.L. Effects of GLP-1 and exendins on kinase activity, 2-deoxy-D-glucose transport, lipolysis and lipogenesis in adipocytes from normal and streptozotocin-induced type 2 diabetic rats. J Mol Endocrinol 35 (2005) 27-38
17. Villanueva-Peñacarrillo M.L., Puente J., Redondo A., Clemente F., and Valverde I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in NIDDM and IDDM rats. Endocrine 15 (2001) 241-248
18. Arnés L., Moreno P., Nuche-Berenguer B., Valverde I., and Villanueva-Peñacarrillo M.L. Effect of exendin-4 treatment upon glucose uptake parameters in liver and muscle, in normal and type 2 diabetic states. Regul Pept (2009) 88-92
19. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
20. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY (3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
21. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., and Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
22. Acitores A., González N., Sancho V., Valverde I., and Villanueva-Peñacarrillo M.L. Cell signalling of the glucagon like peptide-1 action in rat skeletal muscle. J Endocrinol 180 (2004) 389-398
23. González N., Acitores A., Sancho V., Valverde I., and Villanueva-Peñacarrillo M.L. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126 (2005) 203-211
24. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
25. Villanueva-Peñacarrillo M.L., Delgado E., Trapote M.A., Alcántara A., Clemente F., Luque M.A., Perea A., and Valverde I. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146 (1995) 183-189
26. Delgado E., Luque M.A., Alcántara A., Trapote M.A., Clemente F., Galera C., Valverde I., and Villanueva-Peñacarrillo M.L. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16 (1995) 225-229
27. Arnés L., González N., Tornero-Esteban P., Sancho V., Acitores A., Valverde I., Delgado E., and Villanueva-Peñacarrillo M.L. Characteristics of the GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med 22 1 (2008) 127-132
28. Thorens B. Expression clonning of the pancreatic beta-cell receptor for the gluco-incretin hormone glucagon-like peptide-1. Proc Natl Acad Sci U S A 89 (1992) 8641-8645
29. Villanueva-Peñacarrillo M.L., Alcántara A.I., Clemente F., Delgado E., and Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37 (1994) 1163-1166
30. Luque M.A., González N., Márquez L., Acitores A., Redondo A., Morales M., Valverde I., and Villanueva-Peñacarrillo M.L. GLP-1 and glucose metabolism in human myocytes. J Endocrinol 173 (2002) 465-473
31. Van Daele Pl., Stolk R.P., Burguer H., Algra D., Grobee D.E., Hofman A., Birkenhäger J.C., and Pols H.A. Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam study. Ann Intern Med 122 (1995) 409-414
32. Hirano Y., Kishimoto H., Hagino H., and Teshima R. The change of bone mineral density in secondary osteoporosis and vertebral fracture incidence. J Bone Miner Metab 17 (1999) 119-124
33. Glass D.A., and Karsenty G. Minireview: in vivo analysis of Wnt signaling in bone. Endocrinology 148 6 (2007) 2630-2634
34. Portha B., Picon L., and Rosselin G. Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 17 (1979) 371-377
35. Iwase M., Kikuchi M., Nunoi K., Wakisaka M., Maki Y., Sadoshima S., and Fujishima M. Blood pressure changes in spontaneously hypertensive and normotensive rats with neonatal streptozotocin induced type 2 diabetes. Clin Exp Hypertens A 9 (1987) 2157-2168
36. Cancelas J., Prieto P.G., García-Arévalo M., Villanueva-Peñacarrillo M.L., Malaisse W.J., and Valverde I. Induction and reversibility of insulin resistance in rats exposed to exogenous D-fructose. Horm Metab Res 40 (2008) 459-466
37. Herbert V., Lau K.S., Goltlieb C.W., and Bleicher S.J. Coated charcoal inmunoassay of insulin. J Clin Invest 25 (1956) 1375-1384
38. Valverde I., Barreto M., and Malaisse W.J. Stimulation by D-glucose of protein biosynthesis in tumoral insulin-producing cells (RINm5F line). Endocrinology 122 (1988) 1443-1448
39. Ascencio C., Torres N., Isoard-Acosta F., Gómez-Pérez F.J., Hernández-Pando R., and Tovar A.R. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134 (2004) 522-529
40. Feldkamp L.A., Davis L.C., and Kress J.W. Practical cone-beam algorithm. J Opt Soc Am A 1 (1984) 612-619
41. Hofbauer L., Brueck C.C., Singh S.K., and Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22 (2007) 1317-1328
42. Saito M., Fujii K., and Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17 (2006) 1514-1523
43. Vilsbøll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 30 (2001) 609-613
44. Cancelas J., Villanueva-Peñacarrillo M.L., Valverde I., and Malaisse W.J. Synergistic insulinotropic effects of succinic acid dimethyl ester and exendin-4 in anaesthetized rats. Int J Mol Med 8 (2001) 269-271
45. Thrailkill K.M., Liu L., Wahl E.C., Bunn R.C., Perrien D.S., Cockrell G.E., Skinner R.A., Hogue W.R., Carver A.A., Fowlkes J.L., Aronson J., and Lumpkin Jr. C.K. Bone formation is impaired in a model of type 1 diabetes. Diabetes 54 (2005) 2875-2881
46. Krishnan V., Bryant H.U., and MacDougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest 116 5 (2006) 1202-1209
47. Glass II D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., Taketo M.M., Long F., McMahon A.P., Lang R.A., and Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8 (2005) 727-738
48. Power R.A., Iwaniec U.T., Magee K.A., Mitova-Caneva N.G., and Wronski T.J. Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos Int 15 (2004) 716-723
49. Yang H., Egan J.M., Wang Y., Moyes D., Roth J., Montrose M.H., and Montrose-Rafizadeh. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275 (1998) 675-683
50. Márquez L., Trapote M.A., Luque M.A., Valverde I., and Villanueva-Peñacarrilo M.L. Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide 1(7-36) amide on rat liver and adipose tissue. Cell Biochem Funct 16 (1998) 51-56